| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/09/2007 | EP1781652A1 Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists |
| 05/09/2007 | EP1781650A1 Novel compounds having an anti-bacterial activity |
| 05/09/2007 | EP1781649A2 Substituted hydantoins |
| 05/09/2007 | EP1781648A2 1,3,4-oxadiazol-2-ones as ppar delta modulators |
| 05/09/2007 | EP1781645A1 Oxazolo-naphthyl acids as plasminogen activator inhibitor type-1(pai-1) modulators useful in the treatment of thrombosis and cardiovascular diseases |
| 05/09/2007 | EP1781644A1 Macrocyclic beta-secretase inhibitors |
| 05/09/2007 | EP1781643A1 Oxindole oxazolidinones as antibacterial agents |
| 05/09/2007 | EP1781642A1 Oxazolidinones containing oxindoles as antibacterial agents |
| 05/09/2007 | EP1781641A1 Pyrrolo-naphthyl acids as pai-1 inhibitors |
| 05/09/2007 | EP1781640A1 2,4-di(aminophenyl)pyrimidine derivatives as plk inhibitors |
| 05/09/2007 | EP1781639A1 Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
| 05/09/2007 | EP1781638A2 Imidazolo-related compounds, compositions and methods for their use |
| 05/09/2007 | EP1781637A1 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
| 05/09/2007 | EP1781636A1 Pyrrole derivatives, their preparation and their therapeutic use |
| 05/09/2007 | EP1781635A2 Potassium channel inhibitors |
| 05/09/2007 | EP1781633A1 Novel antidiabetic compounds |
| 05/09/2007 | EP1781632A1 Pyrans for use in the treatment of infection |
| 05/09/2007 | EP1781631A1 Diarylmethyl piperazine derivatives, preparations thereof and uses thereof |
| 05/09/2007 | EP1781630A1 Novel piperidine derivative for the treatment of depression |
| 05/09/2007 | EP1781628A2 Prodrug substituted benzoxazoles as estrogenic agents |
| 05/09/2007 | EP1781625A1 Substituted amide beta secretase inhibitors |
| 05/09/2007 | EP1781623A1 Compounds and compositions useful as cathepsin s inhibitors |
| 05/09/2007 | EP1781622A2 Integrin alpha-v beta-3 antagonists for use in imaging and therapy |
| 05/09/2007 | EP1781621A1 Pyridazin-3(2h)-one derivatives and their use as pde4 inhibitors |
| 05/09/2007 | EP1781620A1 Novel beta agonists, method for producing the same and their use as drugs |
| 05/09/2007 | EP1781619A1 Sigma receptor inhibitors |
| 05/09/2007 | EP1781618A1 Sigma receptor inhibitors |
| 05/09/2007 | EP1781614A1 Compounds which potentiate glutamate receptor and uses thereof in medicine |
| 05/09/2007 | EP1781613A1 Piperidine derivatives as histamine h3 receptor ligands |
| 05/09/2007 | EP1781612A1 Shortened method for the production of l-lobeline |
| 05/09/2007 | EP1781608A1 Indole derivatives comprising an acetylene group as ppar activators |
| 05/09/2007 | EP1781607A2 Pyrrolidine derivatives as muscarinic receptor antagonists |
| 05/09/2007 | EP1781606A2 Azetidine derivatives as ccr-3 receptor antagonists |
| 05/09/2007 | EP1781604A1 Bis(thio-hydrazide amide) salts for treatment of cancers |
| 05/09/2007 | EP1781602A1 4-sulfonyl-substituted benzoylalanine derivatives useful as kynurenine-aminotransferase inhibitors |
| 05/09/2007 | EP1781601A2 Derivatives of arylsulfonamido-substituted hydroxamic acid as matrix metalloproteinases inhibitors |
| 05/09/2007 | EP1781600A1 Benzoic acid derivatives as non-nucleoside reverse transcriptase inhibitors |
| 05/09/2007 | EP1781599A1 Androgen modulators |
| 05/09/2007 | EP1781598A1 Androgen modulators |
| 05/09/2007 | EP1781596A1 Amino acid derived prodrugs of propofol compositions and uses thereof |
| 05/09/2007 | EP1781595A1 Methods and compositions for modulating sphingosine-1-phosphate (s1p) receptor activity |
| 05/09/2007 | EP1781593A2 Cationic lipids and methods of use |
| 05/09/2007 | EP1781375A2 Mixture of catechins or polyphenols extracted from chinese green tea or other vegetables for the prevention of prostate cancer and for the treatment of prostate hypertrophy (bph) |
| 05/09/2007 | EP1781337A2 Methods and compositions for cell activation |
| 05/09/2007 | EP1781333A2 Compositions and methods for nutrition supplementation |
| 05/09/2007 | EP1781330A1 Compositions containing a capillary active system with application-related differentiability, and the use thereof |
| 05/09/2007 | EP1781329A1 Therapy device and related accessories, compositions, and treatment methods |
| 05/09/2007 | EP1781326A2 Induction of an immune response against streptococcus pneumoniae polysaccharides |
| 05/09/2007 | EP1781306A2 Immune stimulatory infant nutrition |
| 05/09/2007 | EP1781305A2 Compositions and methods using hyaluronic acid and hyaluronidase inhibitors |
| 05/09/2007 | EP1781304A1 Use of organic glucosamine salts |
| 05/09/2007 | EP1781303A1 Methods and reagents for the treatment of metabolic disorders |
| 05/09/2007 | EP1781302A1 New use |
| 05/09/2007 | EP1781301A2 Angiostatic agents for controlling choroidal neovascularisation after ocular surgery or trauma |
| 05/09/2007 | EP1781300A1 Muscarinic antagonists with parp and sir modulatng activity as agents for inflammatory diseases |
| 05/09/2007 | EP1781299A1 Anti-inflammatory agents |
| 05/09/2007 | EP1781298A1 Pharmaceutical combinations containing benzoxazine for treating respiratory diseases |
| 05/09/2007 | EP1781297A1 Novel biaromatic compounds that activate ppar type receptors, and use thereof in cosmetic or pharmaceutical compositions |
| 05/09/2007 | EP1781296A2 Quinazoline derivatives and their use in the treatment of thrombocythemia |
| 05/09/2007 | EP1781295A1 Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle |
| 05/09/2007 | EP1781294A2 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid |
| 05/09/2007 | EP1781293A1 Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 05/09/2007 | EP1781292A1 Extended release formulation of 3-amino-8-(1-piperazinyl)-2h-1benzopyran-2-one |
| 05/09/2007 | EP1781291A1 Opioids for the treatment of the restlessness of the lower limbs |
| 05/09/2007 | EP1781290A2 Anti-inflammatory agents |
| 05/09/2007 | EP1781289A1 Thienopyridines for treating hepatitis c |
| 05/09/2007 | EP1781288A2 Modulators of muscarinic receptors |
| 05/09/2007 | EP1781287A2 Thiazole based inhibitors of atp-utilizing enyzmes |
| 05/09/2007 | EP1781286A2 Mitotic kinesin inhibitors |
| 05/09/2007 | EP1781285A2 Mitotic kinesin inhibitors |
| 05/09/2007 | EP1781284A1 Use of the combination comprising temozolomide and tnf-alpha for treating glioblastoma |
| 05/09/2007 | EP1781283A2 Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists |
| 05/09/2007 | EP1781282A1 Composition for stabilizing vitamin c in water phase and method for stabilizing vitamin c using thereof |
| 05/09/2007 | EP1781281A1 Compositions for urinary dysfunction and edema containing decursin and/or decursinol angelate, or angelica extract containing decursin and /or decursinol angelate |
| 05/09/2007 | EP1781280A2 Androgen modulators |
| 05/09/2007 | EP1781279A2 Preparation for the prevention and treatment of stress conditions as well as functional and organic disorders of the nervous system and metabolic disorders |
| 05/09/2007 | EP1781278A1 Compositions and methods for treating eye disorders and conditions |
| 05/09/2007 | EP1781277A2 A combination composition |
| 05/09/2007 | EP1781276A2 Use of peptide compounds for treating bone cancer pain, chemotherapy- and nucleoside-induced pain |
| 05/09/2007 | EP1781275A1 Sustained release pharmaceutical composition of tolterodine |
| 05/09/2007 | EP1781274A1 Novel biaromatic compounds which activate receptors of ppar type and their use in cosmetic or pharmaceutical compositions |
| 05/09/2007 | EP1781273A2 Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
| 05/09/2007 | EP1781272A1 Use of compounds active on the sigma receptor for the treatment of mechanical allodynia |
| 05/09/2007 | EP1781271A1 Arylidenes for the treatment of estrogen related receptor-alpha mediated diseases |
| 05/09/2007 | EP1781270A2 Resorcinol derivatives for lowering blood pressure |
| 05/09/2007 | EP1781268A1 Treatment of myocardial infarction with 11hsd1 inhibitors |
| 05/09/2007 | EP1781267A2 Methods and reagents for the treatment of immunoinflammatory disorders |
| 05/09/2007 | EP1781265A2 Pharmaceutical formulations of potassium atp channel openers and uses thereof |
| 05/09/2007 | EP1781264A2 Methods for manufacturing delivery devices and devices thereof |
| 05/09/2007 | EP1781261A1 Modified release formulation of memantine |
| 05/09/2007 | EP1781260A1 Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof |
| 05/09/2007 | EP1781256A1 Phospholipid gel compositions for drug delivery and methods of treating conditions using same |
| 05/09/2007 | EP1781255A1 Compositions and methods for treating leukemia |
| 05/09/2007 | EP1781220A2 Biocompatible polymeric vesicles self assembled from triblock copolymers |
| 05/09/2007 | EP1781119A1 Lipoic acid concentrate |
| 05/09/2007 | EP1781117A1 Composition containing fermentable polysaccharides |
| 05/09/2007 | EP1781115A1 Food supplement for livestock and implementing method thereof |
| 05/09/2007 | EP1781108A2 Use of methyl pyruvate for the purpose of increasing muscle energy production |
| 05/09/2007 | EP1781104A2 Muscarinic acetylcholine receptor antagonists |
| 05/09/2007 | EP1781103A2 Muscarinic acetylcholine receptor antagonists |